New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 27, 2014
07:02 EDTINCY, BMYBristol-Myers, Incyte enter collaboration agreement for nivolumab, INCB24360
Bristol-Myers Squibb (BMY) and Incyte (INCY) announced the establishment of a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of a combination regimen of Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor, nivolumab, and Incyte’s oral indoleamine dioxygenase-1 inhibitor, INCB24360, in a Phase I/II study. Multiple tumor types will be explored in the study, which could potentially include melanoma, non-small cell lung, ovarian, colorectal, squamous cell carcinoma of the head and neck and diffuse large B-cell lymphoma. The study, which is expected to begin in 4Q, will be co-funded by the companies and conducted by Incyte. Additional details of the collaboration were not disclosed.
News For BMY;INCY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
May 29, 2015
14:58 EDTBMYBristol-Myers Opdivo data opens door for competition, Schoenebaum says
Subscribe for More Information
14:49 EDTBMYBristol-Myers tumbles in late afternoon trading
Subscribe for More Information
14:27 EDTBMYBristol-Myers down 4.5% after reporting on Opdivo trials
Subscribe for More Information
14:06 EDTBMYBristol says Opdivo demonstrates anti-tumor activity in hepatocellular carcinoma
Subscribe for More Information
14:04 EDTBMYBristol-Myers says Opdivo demonstrates superior OS versus standard of care
Bristol-Myers Squibb announced that Opdivo is the first PD-1 inhibitor to demonstrate superior overall survival versus standard of care, or docetaxel, in an open-label, randomized Phase III study evaluating previously-treated patients with advanced, non-squamous non-small cell lung cancer, or NSCLC. A 27% reduction in the risk of progression or death – the primary study endpoint – was reported for Opdivo versus docetaxel based upon a hazard ratio of 0.73. Opdivo was associated with a doubling of overall median survival across the continuum of PD-L1 expression, starting at 1% level of expression, in the trial. The safety profile of Opdivo in CheckMate -057 was favorable versus docetaxel with grade 3–5 treatment-related adverse events reported in 10% of patients who were treated with Opdivo versus 54% in the docetaxel arm. These data will be featured today, May 29, during the 51st Annual Meeting of the American Society of Clinical Oncology press briefing and presented during a clinical science symposium on Saturday, May 30, the company noted.
07:52 EDTINCYIncyte reinstated with a Buy at BofA/Merrill
Subscribe for More Information
May 28, 2015
15:11 EDTBMYBristol-Myers to hold a conference call
Subscribe for More Information
11:22 EDTBMYCatalyst Pharmaceutical names Richard Daly as interim Chief Commercial Officer
Subscribe for More Information
May 27, 2015
07:33 EDTINCYIncyte says clinical portfolio to be featured in 23 abstract presentations
Incyte Corporation (INCY) announced that 23 abstracts detailing studies from its clinical development pipeline, including those conducted by Incyte, Novartis (NVS) and independent investigators, will be presented at the 2015 American Society of Clinical Oncology and European Hematology Association annual meetings. These conferences will take place from May 29th – June 2nd in Chicago, IL and June 11th – 14th in Vienna, Austria. “The abstracts to be presented at ASCO and EHA showcase the depth and breadth of our development pipeline in oncology, as well as the success of our collaboration with Novartis,” stated Rich Levy, MD, Incyte’s Chief Drug Development Officer. “Incyte is committed to translating R&D excellence into new medicines which can improve patients’ lives, and these data, including novel:novel combinations from within our portfolio, provide further evidence of our ongoing progress.”
May 26, 2015
09:38 EDTBMYuniQure reports collaboration with Bristol-Myers closed, triggers $50M payment
uniQure (QURE) announced the closing of its strategic collaboration with Bristol-Myers Squibb (BMY) to develop gene therapies for cardiovascular disease. The transaction was previously announced on April 6. Under the terms of the agreement, Bristol-Myers Squibb will make near-term payments of approximately $100M, including an initial upfront payment of $50M upon closing of the transaction, a $15M payment upon selection of three collaboration targets, in addition to S100A1, to be made within three months of closing, and an initial equity investment in uniQure representing 4.9% of the total number of shares outstanding following such issuance, at a purchase price of $33.84 per share, or approximately $37M in total. The initial equity investment is expected to close on June 12. Bristol-Myers-Squibb will acquire an additional 5.0% ownership before December 31, at a 10% premium, and has been granted two warrants, each to acquire up to an additional 5% equity interest, at a premium, based on additional targets being introduced into the collaboration. The parties have also agreed to enter into a supply contract, under which uniQure will undertake manufacturing of all gene therapy products under the collaboration. uniQure will also be eligible to receive research, development and regulatory milestone payments, including up to $254M for the lead S1A001 therapeutic and up to $217M for each other gene therapy product potentially developed under the collaboration. Additionally, uniQure is eligible to receive net sales based milestone payments and tiered single to double-digit royalties on product sales.
07:37 EDTBMYBristol-Myers opportunity in renal cell over $2B, says JPMorgan
Subscribe for More Information
May 22, 2015
10:52 EDTBMYJPMorgan says Actavis shares cheap compared to peers
Subscribe for More Information
07:33 EDTBMYBristol-Myers receives positive CHMP opinion for Nivolumab
Subscribe for More Information
May 21, 2015
07:37 EDTBMYPfizer replaces AbbVie as top global pharma pick at Jefferies
Subscribe for More Information
May 20, 2015
09:01 EDTBMYBristol-Myers receives amended breakthrough therapy designation for daclatasvir
Subscribe for More Information
07:21 EDTBMYUBS to hold a conference
Subscribe for More Information
May 19, 2015
08:57 EDTBMYLeerink biotech analyst holds an analyst/industry conference call
Subscribe for More Information
07:56 EDTBMYGilead for Achillion rumor not ridiculous, but highly unlikely, TheStreet says
Subscribe for More Information
07:45 EDTBMYJacobs Engineering receives contract from Bristol-Myers
Jacobs Engineering (JEC) received a contract from Bristol-Myers Squibb Company (BMY) to provide construction management services for a new large-scale biologics manufacturing facility in Cruiserath, County Dublin, Ireland. Jacobs is also providing architectural and engineering services for the facility, which is being built to produce multiple therapies for the company’s robust and growing portfolio of approved and investigational biologic medicines, and to increase Bristol-Myers Squibb’s biologics manufacturing capacity. The new facility is expected to include multiple large scale bioreactors, a purification area, as well as office and laboratory space. Bristol-Myers Squibb’s Board of Directors has approved initial funding that will support the first phase of the project, with the full cost of the facility expected to be finalized in the second half of 2015. The facility is estimated to be operational in 2019.
07:22 EDTINCYIncyte has a conference call hosted by JPMorgan
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use